Harrow Health, Inc. (NASDAQ: HROW) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $1.1B. The Maz Rating grades it against the other companies in its sector.
Harrow Health, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $29.52, Harrow Health, Inc. trades at 3.6x sales and 37.5x book value, with an EV/EBITDA of 79.5. Over the last twelve months it generated about $307M of revenue and a net loss of $29M. It runs a gross margin of 73.5%, an operating margin of 0.8% and a net margin of -9.4%. It shows return on equity of -90.8%, return on invested capital of 0.7% and a free cash flow yield of -1.8%. On the balance sheet: a debt-to-equity ratio of 10.31 and a current ratio of 2.29. Over the past 52 weeks the share price ranged from $25.76 to $54.85, with a beta of 0.24.
Harrow Health, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 10 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.